Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinqiao Xiashi Fang is a Traditional Chinese Medicine (TCM) herbal formula developed for the treatment of respiratory viral infections, notably gaining prominence during the COVID-19 pandemic. The formula is composed of several botanical ingredients, including *Lonicera japonica* (honeysuckle), *Forsythia suspensa*, *Prunella vulgaris*, and *Gypsum fibrosum*. It is designed to clear heat, detoxify, and resolve phlegm according to TCM principles. Clinically, it has been utilized to treat mild to moderate cases of COVID-19 and other viral pneumonias, showing potential in reducing fever, alleviating cough, and preventing the progression of the disease to severe stages. It was notably included in the Beijing COVID-19 diagnosis and treatment plan as a recommended hospital preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinqiao Xiashi Fang.